Biomarkers of Kidney Function in Transplant Medicine

NCT ID: NCT05538234

Last Updated: 2023-09-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-01

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Biomarkers of kidney function in transplant medicine is an international, multicentre, observational, non-interventional study.

The project is aimed at monitoring biomarkers of acute kidney dysfunction in deceased organ donors, living organ donors, and organ recipients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is observational, without any changes from the standard care, including only selected laboratory assessments, from standard blood samples collected from the donors/recipients.

Informed consent will be required from living donors and recipients.

The mainly used current criteria of organ acceptability in transplant medicine include urine output and laboratory parameters of acute kidney dysfunction - serum levels of urea and creatinine. Literary sources show that these classic criteria of kidney dysfunction develop only with a significant reduction of (glomerular and tubular) kidney functions and return to normal only slowly after the function of the kidneys has been restored.

New possibilities of early kidney dysfunction diagnostics are being studied, using more sensitive tests - determination of biomarkers of acute kidney dysfunction. These may serve as decisive criteria for the safe use of organs from so-called marginal donors and identify early serious impairment of kidney function in donors with preserved urine output, without fulfilled criteria of acute kidney injury.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-living organ donors

Group of non-living donors

Laboratory values - baseline

Intervention Type DIAGNOSTIC_TEST

Baseline laboratory values will be obtained

Medical information 12 hours before organ harvesting

Intervention Type OTHER

* average hourly diuresis
* hypotension MAP\<65 Torr longer than 30 minutes (YES/NO)
* Furosemide administration (YES/NO)
* Mannitol administration (YES/NO)
* administration of anti-diuretic hormone (YES/NO)
* administration of vasopressors (YES/NO)
* polyuria \>3ml/kg/h (YES/NO)
* nephrotoxic agents during hospitalization (YES/NO)

Medical information during organ harvesting/transplantation

Intervention Type OTHER

Medical information during organ harvesting/transplantation

* hypotension MAP 65 Torr \> 5 minutes (YES/NO)
* vasopressor support (YES/NO, duration in minutes)

Organ harvesting

Intervention Type PROCEDURE

Organ harvesting for transplant

Living organ donors

Group of living organ donors

Laboratory values - baseline

Intervention Type DIAGNOSTIC_TEST

Baseline laboratory values will be obtained

Laboratory values - 12 hours after reperfusion

Intervention Type DIAGNOSTIC_TEST

Laboratory values will be obtained 12 hours after reperfusion

Laboratory values - 48 hours after reperfusion

Intervention Type DIAGNOSTIC_TEST

Laboratory values will be obtained 48 hours after reperfusion

Laboratory values - 7 days after reperfusion

Intervention Type DIAGNOSTIC_TEST

Laboratory values will be obtained 7 days after reperfusion

Laboratory values - 90 days after reperfusion

Intervention Type DIAGNOSTIC_TEST

Laboratory values will be obtained 90 days after reperfusion

Medical information during organ harvesting/transplantation

Intervention Type OTHER

Medical information during organ harvesting/transplantation

* hypotension MAP 65 Torr \> 5 minutes (YES/NO)
* vasopressor support (YES/NO, duration in minutes)

Organ harvesting

Intervention Type PROCEDURE

Organ harvesting for transplant

Organ recipients

Group of organ recipients

Laboratory values - baseline

Intervention Type DIAGNOSTIC_TEST

Baseline laboratory values will be obtained

Laboratory values - 12 hours after reperfusion

Intervention Type DIAGNOSTIC_TEST

Laboratory values will be obtained 12 hours after reperfusion

Laboratory values - 48 hours after reperfusion

Intervention Type DIAGNOSTIC_TEST

Laboratory values will be obtained 48 hours after reperfusion

Laboratory values - 7 days after reperfusion

Intervention Type DIAGNOSTIC_TEST

Laboratory values will be obtained 7 days after reperfusion

Laboratory values - 90 days after reperfusion

Intervention Type DIAGNOSTIC_TEST

Laboratory values will be obtained 90 days after reperfusion

Medical information during organ harvesting/transplantation

Intervention Type OTHER

Medical information during organ harvesting/transplantation

* hypotension MAP 65 Torr \> 5 minutes (YES/NO)
* vasopressor support (YES/NO, duration in minutes)

Organ transplantation

Intervention Type PROCEDURE

Transplantation of the harvested organ

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Laboratory values - baseline

Baseline laboratory values will be obtained

Intervention Type DIAGNOSTIC_TEST

Medical information 12 hours before organ harvesting

* average hourly diuresis
* hypotension MAP\<65 Torr longer than 30 minutes (YES/NO)
* Furosemide administration (YES/NO)
* Mannitol administration (YES/NO)
* administration of anti-diuretic hormone (YES/NO)
* administration of vasopressors (YES/NO)
* polyuria \>3ml/kg/h (YES/NO)
* nephrotoxic agents during hospitalization (YES/NO)

Intervention Type OTHER

Laboratory values - 12 hours after reperfusion

Laboratory values will be obtained 12 hours after reperfusion

Intervention Type DIAGNOSTIC_TEST

Laboratory values - 48 hours after reperfusion

Laboratory values will be obtained 48 hours after reperfusion

Intervention Type DIAGNOSTIC_TEST

Laboratory values - 7 days after reperfusion

Laboratory values will be obtained 7 days after reperfusion

Intervention Type DIAGNOSTIC_TEST

Laboratory values - 90 days after reperfusion

Laboratory values will be obtained 90 days after reperfusion

Intervention Type DIAGNOSTIC_TEST

Medical information during organ harvesting/transplantation

Medical information during organ harvesting/transplantation

* hypotension MAP 65 Torr \> 5 minutes (YES/NO)
* vasopressor support (YES/NO, duration in minutes)

Intervention Type OTHER

Organ harvesting

Organ harvesting for transplant

Intervention Type PROCEDURE

Organ transplantation

Transplantation of the harvested organ

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 18+
* signed Informed Consent in case of living organ donors and recipients
* fulfillment of all legal requirements for organ harvesting from a deceased donor
* fulfillment of all ethical principles of end-of-life patient care
* medical suitability of organs for transplant use

Exclusion Criteria

\- disapproval of family members with the enrolment of the patient in the study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Ostrava

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter Sklienka, MD, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University Hospital Ostrava

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Ostrava

Ostrava, Moravian-Silesian Region, Czechia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Czechia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jiří Hynčica

Role: CONTACT

0042059737 ext. 2587

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jiří Hynčica

Role: primary

0042059737 ext. 2587

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KARIM-827/2021

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.